| Executive Summary: | Nanomics BioSciences, a Delaware “C” corporation, offers gene and protein expression profiling services to screen for efficacy and adverse effects and to identify biomarkers. Our services are at the intersection of biotechnology and nanotechnology. Our addressable market includes government agencies, pharmaceutical and chemical manufacturers, small to medium biotechnology and nanotechnology companies as well as any non-profit and academic groups wishing to develop therapeutics, devices, chemicals, and nanomaterials. A future capability is to develop diagnostic assays for the identified biomarkers.
Nanomics BioSciences is based on Dr. Mary Jane Cunningham’s expertise in gene and protein expression profiling, systems biology, and nanotoxicology. She was a founder of the field of toxicogenomics, holds several patents, and was one of the first toxicologists to investigate the safety of nanomaterials.
Nanomics BioSciences strives to be the premier comprehensive provider of screening and diagnostic capabilities in gene and protein expression profiling and nanotechnology. Regulatory guidelines are being established worldwide for efficacy and safety screens of nanomaterials and the nanotechnology and biomarker diagnostic markets are anticipated to be a multi-billion market in the next few years. We are seeking scientific expertise in diagnostics as well as partners desiring to invest in these leading-edge goals. |
